December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

227.01 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
94 95 Next >
News headline image
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
The Smartest Dividend Stocks to Buy With $250 Right Now ↗
$250 will go a long way with these great dividend stocks. 
Via The Motley Fool
News headline image
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO ↗
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
News headline image
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
News headline image
A Closer Look at AbbVie's Options Market Dynamics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts ↗
 
Via Benzinga
News headline image
Looking At AbbVie's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With ABBV ↗
 
Via Benzinga
News headline image
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
News headline image
New Golden Investment: Universal Health Realty Income Trust ↗
A Golden Investment is one in which I have fully recovered my entire investment either through dividends or from partial liquidation or a combination of both. 
Via Talk Markets
News headline image
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven ↗
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
News headline image
3 Under-the-Radar Biotech Stocks With Blockbuster Potential ↗
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
News headline image
AbbVie Stock Price Forecast: $200 On The Cards? ↗
Strategic partnerships and acquisitions enhance AbbVie's pipeline. 
Via Talk Markets
News headline image
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
3 Retirement All-Stars for Steady Growth and Income ↗
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement. 
Via InvestorPlace
Topics Retirement
News headline image
Cash Flow Alert: 3 Stocks That Just Raised Their Dividends ↗
These dividend growth stocks all have a long history of double-digit dividend increases and just announced another. 
Via InvestorPlace
News headline image
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July ↗
These reliable dividend payers are no-brainer buys right now. 
Via The Motley Fool
News headline image
3 Magnificent Stocks Retirees Can Buy and Hold Forever ↗
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
News headline image
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet ↗
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
News headline image
7 Dividend Kings to Buy With Your Roth IRA Money in 2024 ↗
These seven Dividend Kings offer reliable income streams and long-term growth potential, making them ideal holdings for your Roth IRA. 
Via InvestorPlace
News headline image
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
News headline image
Can AbbVie Stock Keep Outpacing the S&P 500? ↗
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up? 
Via The Motley Fool
Topics Stocks
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock ↗
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues. ABBV-951, a treatment for advanced Parkinson's, is approved in 34... 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income ↗
Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true. 
Via The Motley Fool
News headline image
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income ↗
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
News headline image
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22 ↗
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
News headline image
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal ↗
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
News headline image
3 Biotech Stocks to Buy Now: June 2024 ↗
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024 ↗
Discover top retirement stocks with strong buy ratings, offering reliable growth and income to ensure a comfortable retirement. 
Via InvestorPlace
Topics Retirement
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
94 95 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.